London-based Perceptic closed a $12 million seed round led by Accel to expand its end-to-end AI platform for pharmaceutical development. The startup was founded by three former Palantir executives who built Palantir's Life Sciences practice.
Perceptic positions itself as a comprehensive AI solution for drug development, with backing from top pharmaceutical companies already using the platform. The funding comes as the biotech sector increasingly adopts machine learning to accelerate research and reduce development timelines.
The startup's founding team brings significant enterprise software experience from Palantir, where they developed tools for intelligence and data analysis. This expertise translates directly to pharma's complex data challenges around molecular analysis, clinical trials, and drug candidate identification.
Ackel's investment signals confidence in AI-driven drug development as a category. The $12 million seed round will likely fund platform expansion and talent recruitment. Perceptic joins a growing cohort of AI-first biotech platforms targeting the $2 trillion pharmaceutical industry.
The company operates in a competitive space alongside initiatives from established pharma giants and well-funded startups, though its enterprise pedigree differentiates its approach to regulatory-grade AI systems.
Newlight has secured $9 million in seed funding to develop hydrogen fuel-injection technology for maritime vessels. The company completed an 8,500-nautical-mile test run from Singapore to Ghana.
Indian edtech startup upGrad has completed its acquisition of rival Unacademy in an all-stock transaction valuing the company at approximately $206 million. The deal marks a dramatic decline from Unacademy's peak valuation of $3.5 billion.
Physics-focused AI startup PSI has emerged from stealth with $58 million in seed funding. The company aims to use artificial intelligence to accelerate the discovery of new physics, including potential solutions for interstellar travel.
India's Unacademy has sold to rival upGrad for $206 million, a dramatic 94% decline from its peak valuation. Co-founder Gaurav Munjal acknowledged the sharp downturn without embellishment.